Sarepta Therapeutics Inc. announced the advancement of its siRNA collaboration, specifically highlighting progress in the Phase 1/2 clinical study of SRP-1003, an investigational RNA interference therapeutic aimed at treating type 1 myotonic dystrophy $(DM1.AU)$. The company reported that a $100 million milestone payment obligation was triggered after achieving a predetermined enrollment target in the study. Sarepta plans to release preliminary data from this study in the second half of 2025. Additionally, Sarepta has sold a portion of its common stock holdings in Arrowhead Pharmaceuticals, Inc. to generate at least $174 million in gross proceeds and has made arrangements to transfer shares to Arrowhead to fulfill part of the milestone payment. The company emphasizes that these financial moves are strategic and do not reflect a change in their belief in the potential of siRNA technology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.